Amarin Corp PLC (NASDAQ:AMRN): Positive Stock Sentiment

Amarin Corporation plc (NASDAQ:AMRN) Logo

Sentiment for Amarin Corp PLC (NASDAQ:AMRN)

Amarin Corp PLC (NASDAQ:AMRN) institutional sentiment increased to 1.65 in 2018 Q4. Its up 0.02, from 1.63 in 2018Q3. The ratio increased, as 107 active investment managers started new or increased stock positions, while 65 decreased and sold their equity positions in Amarin Corp PLC. The active investment managers in our partner’s database now own: 139.69 million shares, up from 126.12 million shares in 2018Q3. Also, the number of active investment managers holding Amarin Corp PLC in their top 10 stock positions increased from 7 to 10 for an increase of 3. Sold All: 18 Reduced: 47 Increased: 41 New Position: 66.

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company has market cap of $5.75 billion. The companyÂ’s lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It currently has negative earnings. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels.

The stock decreased 0.46% or $0.08 during the last trading session, reaching $17.39. About 2.21M shares traded. Amarin Corporation plc (NASDAQ:AMRN) has risen 537.69% since May 8, 2018 and is uptrending. It has outperformed by 533.32% the S&P500.

Analysts await Amarin Corporation plc (NASDAQ:AMRN) to report earnings on August, 7. They expect $-0.06 EPS, up 50.00 % or $0.06 from last year’s $-0.12 per share. After $-0.07 actual EPS reported by Amarin Corporation plc for the previous quarter, Wall Street now forecasts -14.29 % EPS growth.

Oracle Investment Management Inc holds 21.96% of its portfolio in Amarin Corporation plc for 5.20 million shares. Apis Capital Advisors Llc owns 1.16 million shares or 21.2% of their US portfolio. Moreover, Consonance Capital Management Lp has 9.46% invested in the company for 9.45 million shares. The Massachusetts-based Opaleye Management Inc. has invested 6.35% in the stock. Baker Bros. Advisors Lp, a New York-based fund reported 42.59 million shares.

Since January 1, 0001, it had 0 insider buys, and 15 selling transactions for $40.01 million activity.

Amarin Corporation plc (NASDAQ:AMRN) Ratings Coverage

Ratings analysis reveals 100% of Amarin’s analysts are positive. Out of 4 Wall Street analysts rating Amarin, 4 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $27 while the high is $51. The stock’s average target of $35.75 is 105.58% above today’s ($17.39) share price. AMRN was included in 10 notes of analysts from February 22, 2019. Cantor Fitzgerald maintained Amarin Corporation plc (NASDAQ:AMRN) rating on Friday, March 8. Cantor Fitzgerald has “Buy” rating and $35 target. The stock has “Buy” rating by Cantor Fitzgerald on Friday, February 22. The firm has “Buy” rating given on Friday, March 22 by Cantor Fitzgerald. The rating was initiated by Stifel Nicolaus with “Buy” on Thursday, March 21. Cantor Fitzgerald maintained Amarin Corporation plc (NASDAQ:AMRN) on Friday, March 15 with “Buy” rating. The company was maintained on Wednesday, February 27 by Jefferies. The firm has “Buy” rating given on Thursday, February 28 by H.C. Wainwright. H.C. Wainwright maintained Amarin Corporation plc (NASDAQ:AMRN) rating on Tuesday, March 19. H.C. Wainwright has “Buy” rating and $51 target.

More notable recent Amarin Corporation plc (NASDAQ:AMRN) news were published by: Seekingalpha.com which released: “Amarin misses by $0.02, beats on revenue – Seeking Alpha” on February 27, 2019, also Finance.Yahoo.com with their article: “What Kind Of Investor Owns Most Of Amarin Corporation plc (NASDAQ:AMRN)? – Yahoo Finance” published on April 25, 2019, Nasdaq.com published: “Amarin (AMRN) Beats Estimates for Earnings & Revenues in Q1 – Nasdaq” on May 01, 2019. More interesting news about Amarin Corporation plc (NASDAQ:AMRN) were released by: Globenewswire.com and their article: “New Drug Submission Filed for Vascepa® with Health Canada – GlobeNewswire” published on April 29, 2019 as well as Nasdaq.com‘s news article titled: “Why Amarin’s Stock Sank on Strong First-Quarter Results – Nasdaq” with publication date: May 02, 2019.

Amarin Corporation plc (NASDAQ:AMRN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.